Please assess the completion status of the following clinical trial:

Trial Title: Eltrombopag for Inherited Thrombocytopenias

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Phase 1:~Patients with the following forms of inherited thrombocytopenias will be considered for enrolment:~* MYH9-related disorders (OMIM 155100, 605249, 153640, 153650)~* Bernard-Soulier Syndrome (OMIM 231200) deriving from monoallelic mutations (at variance with biallelic classical BSS, monoallelic form does not present defective platelet function)~* Wiskott-Aldrich syndrome (OMIM 301000).~* X-linked thrombocytopenia (OMIM 313900).~* X-linked thrombocytopenia with thalassemia (OMIM 314050).~* Dyserythropoietic anemia with thrombocytopenia (OMIM 300367).~* ITGA2B/ITGB3-related thrombocytopenia (OMIM not available).~* ANKRD26-related thrombocytopenia (OMIM 188000).~* TUBB1-related thrombocytopenia (OMIM not available)~* ACTN1-related thrombocytopenia (OMIM not available)~* GFI1B-related thrombocytopenia (OMIM not available)~* CYCS-related thrombocytopenia (OMIM 612004)~* SLFN14-related thrombocytopenia (OMIM not available)~Patients will have to fulfill all the following criteria:~* Age ≥ 16 years and ≤ 70 years~* Average platelet count during the previous year less than 80 x109/L~* Written informed consent~Phase 2~Patients with clinically relevant chronic or recurrent bleedings at baseline (grade 2-4 of the WHO bleeding scale) who: (i) completed the phase 1 without severe side effects and (ii) obtained reduction or remission of bleeding by Eltrombopag administration.~Exclusion Criteria:~Phases 1 and 2~* Hypersensitivity to Eltrombopag or one of the excipients.~* History of thromboembolic events.~* Treatment with anti-platelet drugs or other drugs affecting platelet function and/or with anticoagulants.~* Concurrent diseases or conditions that significantly increase the risk of thromboembolic events.~* Moderate to severe liver failure (Child-Pugh score ≥ 5).~* Altered renal function as defined by creatinine ≥ 2 mg/dL~* Previous or concurrent clonal disorders of the myeloid series (acute myeloid leukemias and myelodysplastic syndromes).~* Females who are pregnant or nursing (a negative pregnancy test is required before enrolment of fertile women).~* Formal refusal of any recommendations for a safe contraception.~* Alcohol or drug addiction.~* Any other disease or condition that by the advice of the responsible physician would make the treatment dangerous for the patient or would make the patient ineligible for this study, including physical, psychiatric, social and behavioral problems.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Eltrombopag (Type: EXPERIMENTAL): Phase 1: Eltrombopag 50 mg/day for 3 weeks. At the end of these 3 weeks of treatment: platelet count higher than 100 x10e9/L and no spontaneous bleeding, end therapy. In the other cases, treatment with eltrombopag 75 mg/day for 3 additional weeks.~Phase 2: Eltrombopag will be administered for 16 weeks. Eltrombopag will be initially given at 25 mg/day for 4 weeks. Every 4 weeks, the dosage will be modified as follows. (1) Bleeding score (WHO bleeding scale) 0-1 and platelet count between 30 and 100 x10e9/L: continue at the current dose; (2) Bleeding score 0-1 and platelet count higher than 100 x10e9/L: switch to the next lower dose; (3) Bleeding score 2-4 or platelet count lower than 30 x 10e9/L: switch to the next higher dose. The following dosages of eltrombopag are considered: 12.5 mg/day; 25 mg/day; 50 mg/day; 75 mg/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).